NCT04958044 is a Phase 1 clinical trial of Calcium Gluconate in Esophageal Cancer, sponsored by Michael Patrick Achiam.

Who is sponsoring NCT04958044?

NCT04958044 is sponsored by Michael Patrick Achiam.

What drugs are being tested in NCT04958044?

Interventions in NCT04958044: Calcium Gluconate.

What condition does NCT04958044 study?

NCT04958044 studies Esophageal Cancer.

Is NCT04958044 still recruiting?

NCT04958044 is currently completed. Last updated 26 October 2022.

Last reviewed 2022-10-26 · How we verify

NCT04958044

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Endoscopic Assisted Calcium Electroporation in Esophageal Cancer

Completed Phase 1 Last updated 26 October 2022

What this trial tests

Phase 1 trial testing Calcium Gluconate in Esophageal Cancer in 10 participants. Completed in 13 June 2022.

Timeline

25 May 2021

Primary endpoint
13 June 2022

13 June 2022

Quick facts

Lead sponsor	Michael Patrick Achiam
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	10
Start date	25 May 2021
Primary completion	13 June 2022
Estimated completion	13 June 2022
Sites	1 location across Denmark

Drugs / interventions tested

Calcium Gluconate (CALCIUM GLUCONATE) — full drug profile →

Conditions studied

Esophageal Cancer — all drugs for Esophageal Cancer →

Sponsor

Michael Patrick Achiam

Who can join

Adults 18 to 100, any sex, with Esophageal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this pilot study, patients with non-curable esophageal cancer will be treated with endoscopic assisted calcium electroporation (CaEP). CaEP is a novel cancer treatment where intratumoral injection with calcium is combined with locally applied electrical pulses, in order to increase calcium influx which leads to tumor necrosis. It is hypothesized that: * Endoscopic assisted CaEP is a safe and feasible procedure in patients with non-curable esophageal cancer * CaEP debulks the tumor, facilitating the patient's ability to eat and drink In this single-arm pilot study, eight patients will be treated.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

The Impact of Calcium Overload on Cellular Processes: Exploring Calcicoptosis and Its Therapeutic Potential in Cancer.
Gielecińska A, Kciuk M, Kontek R. · · 2024 · cited 23× · PMID 39769488 · DOI 10.3390/ijms252413727
Palliative Treatment of Esophageal Cancer Using Calcium Electroporation.
Egeland C, Baeksgaard L, Gehl J, Gögenur I, et al · · 2022 · cited 14× · PMID 36358702 · DOI 10.3390/cancers14215283
Electroporation and Electrochemotherapy in Gynecological and Breast Cancer Treatment.
Łapińska Z, Szwedowicz U, Choromańska A, Saczko J. · · 2022 · cited 11× · PMID 35458673 · DOI 10.3390/molecules27082476

Verify or expand the search:

Other trials of Calcium Gluconate

Trials testing the same drug.

NCT05973747 — Pharmacokinetic Equivalence of Calcium Gluconate and Calcium Chloride in Parturients · EARLY_PHASE1 · completed
NCT06333691 — Comparative Study Between Calcium Gluconate With Diosmin, Cabergoline and Cabergoline With Diosmin · NA · completed
NCT04491357 — Prophylactic Infusion of Calcium Gluconate Reducing the Rate of Hypocalcaemia After Total Thyroidectomy · Phase 4 · unknown
NCT03473613 — Cabergoline Versus Calcium Infusion in Ovarian Hyperstimulation Syndrome Prevention · Phase 3 · completed

Other recruiting trials for Esophageal Cancer

Currently open trials in the same condition.

NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07307560 — High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients · NA · recruiting

Other Michael Patrick Achiam trials

Trials by the same sponsor.

NCT04605419 — Calcium Electroporation in Patients With Cell Changes in the Esophagus · Phase 1 · unknown
NCT04669951 — Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Cancer · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04958044 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Michael Patrick Achiam
Last refreshed: 26 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04958044.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing